(19)
(11) EP 1 395 605 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
17.12.2014 Bulletin 2014/51

(45) Mention of the grant of the patent:
14.05.2014 Bulletin 2014/20

(21) Application number: 02719196.4

(22) Date of filing: 11.03.2002
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
C12N 15/13(2006.01)
C07K 19/00(2006.01)
 C07K 16/00(2006.01)
C12N 15/62(2006.01)
(86) International application number:
PCT/US2002/007365
(87) International publication number:
WO 2002/072608 (19.09.2002 Gazette 2002/38)

(54)

POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCGAMMA RECEPTORS

POLYMERE IMMUNOGLOBULIN-FUSIONSPROTEINE, DIE AUF FC-GAMMA-REZEPTOREN MIT GERINGER AFFINITÄT ZIELEN

PROTEINES HYBRIDES D'IMMUNOGLOBULINES POLYMERIQUES CIBLANT DES RECEPTEURS FCGAMMA A FAIBLE AFFINITE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 09.03.2001 US 274392 P

(43) Date of publication of application:
10.03.2004 Bulletin 2004/11

(73) Proprietor: Iterative Therapeutics, Inc.
Chicago, IL 60612 (US)

(72) Inventors:
  • ARNASON, Barry G.
    Chicago, IL 60615 (US)
  • JENSEN, Mark A.
    Chicago, IL 60657 (US)
  • WHITE, David M.
    Chicago, IL 60615 (US)

(74) Representative: Barton, Matthew Thomas 
Forresters Skygarden Erika-Mann-Strasse 11
80636 München
80636 München (DE)


(56) References cited: : 
WO-A-00/42072
WO-A1-99/58572
 WO-A1-92/10591
   
  • WHITE DAVID M ET AL: "Design and expression of polymeric immunoglobulin fusion proteins: A strategy for targeting low-affinity Fcgamma receptors" PROTEIN EXPRESSION AND PURIFICATION, vol. 21, no. 3, April 2001 (2001-04), pages 446-455, XP002282485 ISSN: 1046-5928
  • SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591-6604, XP002271092 ISSN: 0021-9258
  • MORGAN A ET AL: "THE N-TERMINAL END OF THE CH2 DOMAIN OF CHIMERIC HUMAN IGG1 ANTI-HLA-DR IS NECESSARY FOR C1Q, FCGAMMARI AND FCGAMMARIII BINDING" IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 86, no. 2, October 1995 (1995-10), pages 319-324, XP001106372 ISSN: 0019-2805
  • COLOMA M J ET AL: "DESIGN AND PRODUCTION OF NOVEL TETRAVALENT BISPECIFIC ANTIBODIES" NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 15, no. 2, 1 February 1997 (1997-02-01), pages 159-163, XP000647731 ISSN: 1087-0156
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).